Table 1.
Clinicopathological features of intraductal papillary mucinous neoplasms (IPMNs)
| Total (n = 185) | Low-intermediate grade (n = 134) | High-grade/invasive carcinoma (n = 51) | p | |
|---|---|---|---|---|
| Age (years) | 63.15 ± 9.34 | 63.13 ± 9.12 | 63.18 ± 10.00 | 0.481 |
| Size (cm) | 3.65 ± 2.10 | 3.51 ± 2.17 | 4.02 ± 1.86 | 0.170 |
| Sex (male/female) | 112/73 | 77/57 | 35/16 | 0.165 |
| Type | ||||
| Main | 24 (12.97%) | 9 (6.71%) | 15 (29.41%) | < 0.001 |
| Branch | 97 (52.43%) | 87 (64.92%) | 10 (19.61%) | |
| Mixed | 64 (34.59%) | 38 (28.36%) | 26 (50.98%) | |
| Type2 | ||||
| Main and mixed | 88 (47.57%) | 47 (35.07%) | 41 (80.39%) | < 0.001 |
| Branch | 97 (52.43%) | 87 (64.92%) | 10 (19.61%) | |
| Location | ||||
| Head and neck | 118 (63.78%) | 80 (59.70%) | 37 (72.54%) | 0.118 |
| Body and tail | 67 (36.22%) | 53 (40.30%) | 14(27.45%) | |
| CEA (ng/ml) | 3.43 ± 3.36 | 2.96 ± 1.83 | 4.69 ± 5.51 | < 0.001 |
| CA19-9 (U/ml) | 53.06 ± 221.91 | 31.44 ± 97.69 | 110.55 ± 390.58 | 0.004 |
| MPD diameter (mm) | 5.91 ± 4.31 | 4.88 ± 3.65 | 8.60 ± 4.77 | 0.006 |
| Mural nodule | 23 (12.43%) | 9 (6.72%) | 14 (27.45%) | < 0.001 |
| Lymph node metastasis (yes) | 2 (1.08%) | 0 | 2 (3.92%) | 0.075 |
| Extra-pancreas extension (yes) | 6 (3.24%) | 0 | 6 (11.76%) | < 0.001 |
| Diabetes Mellitus (yes) | 32 (17.29%) | 17 (12.69%) | 15 (29.41%) | 0.007 |
| Symptom (yes) | 80 (43.24%) | 55 (41.04%) | 25 (49.02%) | 0.348 |
| Pancreatitis (yes) | 4 (2.16%) | 4 (2.99%) | 0 | 0.577 |
| Complications (yes) | 67 (36.22%) | 50 (37.31%) | 17 (33.33%) | 0.615 |
CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, MPD main pancreatic duct